RIN Institute Inc

Our company was established in January 2016, for development of anti-cancer antibody drugs both for therapeutic as well as diagnostic uses based upon the research results by Dr. Yasuhiro Matsumura, Director of Research and former Chief of Division of Developmental Therapeutics, EPOC, National Cancer Center (NCC). In March of the same year, we were certified as a spin-out Biotech from NCC. Our research laboratory is a research base to promote efficient collaboration with NCC, and R&D projects of ADCs and a novel potent thrombolytic fusion protein have been advanced. In January 2023, we started Phase 1 trial of our lead pipeline, a humanized anti-TMEM180 antibody at the NCC.We will accelerate development of new innovative antibodies for anti-cancer drugs and diagnostic drugs with the support of NCC.

contact

• 1-13-10-2F Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan
• E-Mail: info●rinmab.co.jp（●を＠に置き換えてください）
• URL: https://rinmab.co.jp/（Linked at external site）